IP Library Granted Patent US 11,110,101
Granted Patent B2
US 11,110,101 · App. 16/867,386 · Granted Sep 7, 2021

Prostate function support formula

Inventor: Bassam Damaj (San Diego, CA)
Assignee: Innovus Pharmaceuticals, Inc.
A61K31/575A61K9/2013A61K9/2054A61K9/2095A61K31/01A61K31/191A61K31/198A61K31/355A61K31/375A61K31/4415A61K33/04A61K33/30A61K33/34A61K36/185A61K36/736A61K36/82A61K36/889A61P13/08A61P13/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,110,101
App. No.
16/867,386
Granted
Sep 7, 2021
Kind
B2
Abstract

The invention provides unit dosage forms and methods that are effective to improve prostate function. Such unit dosage forms and methods are useful to decrease bladder discomfort and improve urinary flow in men.

Claims (12)

1. A method to improve prostate function in a man in need thereof comprising administering a unit dosage form to the man wherein the unit dosage form consists of the active ingredients:

300 mg±15 mg of Saw Palmetto;

450 mg±22.5 mg of Beta-Sitosterol;

150 mg±7.5 mg of Pygeum africanum;

75 mg±3.75 mg of Green Tea extract

15 mg±0.75 mg of Lycopene; and

30 mg±1.5 mg of Stinging Nettle.

2. The method of claim 1 wherein bladder discomfort is decreased.

3. The method of claim 1 wherein the unit dosage form is administered in the form of three capsules or tablets per day.

4. The method of claim 1 wherein the unit dosage form comprises one or more excipients selected from hydroxypropyl methylcellulose, rice concentrate, and silica.

5. The method of claim 1 wherein the unit dosage form comprises one or more excipients selected from gelatin, magnesium stearate, stearic acid, and microcrystalline cellulose.

6. The method of claim 1 wherein the unit dosage form is formulated as a capsule or a tablet.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Jun 14, 2024
From: AVENUE VENTURE OPPORTUNITIES FUND, L.P.
To: INNOVUS PHARMACEUTICALS, INC.
Reel/Frame 067728/0206 →
PARTIAL RELEASE OF SECURITY INTEREST IN PATENTS Recorded Oct 16, 2023
From: ECLIPSE BUSINESS CAPITAL LLC (F/K/A ENCINA BUSINESS CREDIT, LLC), AS AGENT
To: INNOVUS PHARMACEUTICALS, INC.; SEMPRAE LABORATORIES, INC.; AYTU BIOPHARMA, INC.; NOVALERE, INC.
Reel/Frame 065241/0560 →
SECURITY INTEREST Recorded Feb 10, 2022
From: INNOVUS PHARMACEUTICALS, INC.
To: AVENUE VENTURE OPPORTUNITIES FUND II, L.P.
Reel/Frame 058976/0706 →
SECURITY INTEREST Recorded Jan 27, 2022
From: INNOVUS PHARMACEUTICALS, INC.; SEMPRAE LABORATORIES, INC.
To: ECLIPSE BUSINESS CAPITAL LLC (F/K/A ENCINA BUSINESS CREDIT, LLC), AS AGENT
Reel/Frame 058789/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 2020
From: DAMAJ, BASSAM
To: INNOVUS PHARMACEUTICALS, INC.
Reel/Frame 054005/0686 →
Continuity (2)
Division 15829797 · Dec 1, 2017
Related Publication 20200261474A1 · Aug 20, 2020